공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

글루코실세라마이데이스 : 파이프라인 리뷰

Glucosylceramidase - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 359838
페이지 정보 영문 78 Pages
가격
US $ 3,500 ₩ 3,887,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,774,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,661,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


글루코실세라마이데이스 : 파이프라인 리뷰 Glucosylceramidase - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 78 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

글루코실세라마이데이스(Glucosylceramidase)를 표적으로 하는 약제의 적응증, 개발 단계, 작용기서, 투여 경로 및 분자 종류별 분석, 약제의 약리 작용에 관한 설명, 지금까지의 연구 개발 동향, 최신 뉴스와 발표, 약제 개발에 참여하고 있는 주요 기업 개요, 휴지/중지된 프로젝트 정보 등을 전해드립니다.

서론

  • 조사 범위

글루코실세라마이데이스 개요

치료제 개발

글루코실세라마이데이스 : 개발중인 제품 - 개발 단계별

글루코실세라마이데이스 : 개발중인 제품 - 치료 범위별

글루코실세라마이데이스 : 개발중인 제품 - 적응증별

글루코실세라마이데이스 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

글루코실세라마이데이스 : 기업에서 개발중인 제품

글루코실세라마이데이스 : 대학/기관에서 개발중인 제품

글루코실세라마이데이스 : 치료제 평가

  • 단독요법/병용 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

글루코실세라마이데이스 치료제 개발에 참여하고 있는 기업

  • Amicus Therapeutics, Inc.
  • Bioorganic Research and Services S.A.
  • greenovation Biotech GmbH
  • JCR Pharmaceuticals Co., Ltd.
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Shire Plc
  • The International Biotechnology Center(IBC) Generium

약제 개요

글루코실세라마이데이스 : 휴지중인 프로젝트

글루코실세라마이데이스 : 개발이 중지된 제품

글루코실세라마이데이스 : 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.27

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Adienne Pharma & Biotech, H2 2019
  • Pipeline by Alectos Therapeutics, H2 2019
  • Pipeline by Apollo Therapeutics LLC, H2 2019
  • Pipeline by AVROBIO Inc, H2 2019
  • Pipeline by Belrose Pharma Inc, H2 2019
  • Pipeline by Bioasis Technologies Inc, H2 2019
  • Pipeline by Biosidus SA, H2 2019
  • Pipeline by Blue Turtle Bio Technologies Inc, H2 2019
  • Pipeline by Erad Therapeutics Inc, H2 2019
  • Pipeline by Freeline Therapeutics Ltd, H2 2019
  • Pipeline by GT Gain Therapeutics SA, H2 2019
  • Pipeline by Lysosomal Therapeutics Inc, H2 2019
  • Pipeline by Oxyrane Belgium NV, H2 2019
  • Pipeline by Spedding Research Solutions SAS, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Trucode Gene Repair Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Glucosylceramidase belong to the family of hydrolases that catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. Deficiency in Beta-glucocerebrosidase enzymatic activity, results in accumulation of lipid glucocerebroside in tissue macrophages (Gaucher cells). Enzyme replacement therapy leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside.

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 11 and 2 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Parkinson's Disease, Gaucher Disease, Gaucher Disease Type I, Gaucher Disease Type II, Gaucher Disease Type III and Amyotrophic Lateral Sclerosis.

The latest report Glucosylceramidase - Pipeline Review, H2 2019, outlays comprehensive information on the Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45)
  • The report reviews Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Overview
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Companies Involved in Therapeutics Development
  • Adienne Pharma & Biotech
  • Alectos Therapeutics
  • Apollo Therapeutics LLC
  • AVROBIO Inc
  • Belrose Pharma Inc
  • Bioasis Technologies Inc
  • Biosidus SA
  • Blue Turtle Bio Technologies Inc
  • Erad Therapeutics Inc
  • Freeline Therapeutics Ltd
  • GT Gain Therapeutics SA
  • Lysosomal Therapeutics Inc
  • Oxyrane Belgium NV
  • Spedding Research Solutions SAS
  • Takeda Pharmaceutical Co Ltd
  • Trucode Gene Repair Inc
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Drug Profiles
  • ADN-LYS - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ambroxol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ambroxol hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVRRD-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FLT-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Glucocerebrosidase for Genetic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Glucosylceramidase for Gaucher Disease and Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • imiglucerase biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JT-408T - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LTI-291 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCGC-607 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotides to Activate GBA for Gaucher Disease Type I - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotides to Activate GBA for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pcgin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Beta Glucosylceramidase Replacement for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Glucosylceramidase Replacement for Type I and Type III Gaucher's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate GBA for Gaucher Disease and Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate GCase for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Glucocerebrosidase for Gaucher Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • taliglucerase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • velaglucerase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • xB-3007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Dormant Products
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Discontinued Products
  • Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 06, 2019: Freeline to present data on its Gaucher Disease drug candidate FLT-200 at the 61st ASH Annual Meeting
  • Oct 24, 2019: AVROBIO receives Orphan-Drug Designation from the U.S. FDA for AVR-RD-02 for the treatment of Gaucher Disease
  • Sep 23, 2019: Safety and Biomarker effects of novel therapeutic for Parkinson's disease with GBA mutations
  • Jul 05, 2019: Freeline presents preclinical liver-directed AAV gene therapy data at the European Working Group on Gaucher Disease.
  • Apr 26, 2019: AVROBIO highlights the plato platform and Gaucher program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
  • Feb 26, 2019: Gain Therapeutics announces award of grant support from leading Parkinson's Research Foundations to advance its proprietary non competitive molecular chaperones for parkinson's disease
  • Oct 01, 2018: AVROBIO receives no objection to clinical trial application from Health Canada for AVR-RD-02 gene therapy for gaucher disease
  • Jul 17, 2018: Fetal gene therapy prevents fatal neurodegenerative disease
  • Mar 22, 2017: AVROBIO Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease
  • Dec 27, 2016: Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  • Dec 14, 2016: Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  • Nov 22, 2016: Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older
  • Oct 25, 2016: Asthma research unexpectedly yields new treatment approach for inherited enzyme disease
  • Jul 12, 2016: Researchers make advance in possible treatments for Gaucher, Parkinson's diseases
  • Feb 12, 2015: Safety and Efficacy of ELELYSO (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q